Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 14:41:02 29/04/2024 BST 		5-day change 1st Jan Change
105.4 SEK +1.69% Intraday chart for Calliditas Therapeutics AB +4.59% -17.47%
04-25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
04-24 Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings MT

Business Summary

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Number of employees: 181

Sales per Business

SEK in Million2022Weight2023Weight Delta
Therapeutics for Renal Disease Immunoglobulin
90.1 %
376 46.8 % 1,087 90.1 % +189.58%
Outlicensing of Product
6.9 %
422 52.5 % 83 6.9 % -80.39%
Royalty
3.0 %
2 0.3 % 37 3.0 % +1,507.26%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
89.1 %
372 46.4 % 1,076 89.1 % +189.01%
Asia
7.6 %
287 35.7 % 91 7.6 % -68.10%
Europe
3.3 %
144 17.9 % 40 3.3 % -72.48%

Managers

Managers TitleAgeSince
Renée Aguiar-Lucander CEO
 Chief Executive Officer 62 17/05/17
Fredrik Johansson DFI
 Director of Finance/CFO 47 31/07/17
Richard Philipson CTO
 Chief Tech/Sci/R&D Officer 60 23/07/20
Krassimir Mitchev CTO
 Chief Tech/Sci/R&D Officer - 28/02/19
Johan Erik Häggblad CTO
 Chief Tech/Sci/R&D Officer 65 31/03/07
Åsa Hillsten IRC
 Investor Relations Contact - 31/03/23
Monika Tornsen PRN
 Corporate Officer/Principal 45 01-06
Christopher Ngai PRN
 Corporate Officer/Principal - 31/03/20
Frank Bringstrup LAW
 General Counsel 65 31/01/19
Sandra Frithiof HRO
 Human Resources Officer 49 10/07/22

Members of the board

Members of the board TitleAgeSince
Fred Driscoll BRD
 Director/Board Member 74 29/05/23
Henrik Stenqvist BRD
 Director/Board Member 57 31/12/21
Elmar Schnee CHM
 Chairman 65 07/05/19
Hilde Furberg BRD
 Director/Board Member 65 31/08/14
Margareta Elisabeth Björk BRD
 Director/Board Member 63 31/12/21
Diane Parks BRD
 Director/Board Member 72 07/05/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,580,087 43,663,885 ( 73.29 %) 5,908,018 ( 9.916 %) 73.29 %

Shareholders

NameEquities%Valuation
LINC AB
10.01 %
5,963,966 10.01 % 63 M kr
CALLIDITAS THERAPEUTICS AB
9.916 %
5,908,018 9.916 % 63 M kr
BVF Partners LP
9.692 %
5,774,433 9.692 % 61 M kr
Industrifonden
5.280 %
3,145,828 5.280 % 33 M kr
Fjärde AP-fonden
4.470 %
2,663,000 4.470 % 28 M kr
Unionen (Investment Management)
3.310 %
1,972,100 3.310 % 21 M kr
Sofinnova Partners SAS
2.360 %
1,406,090 2.360 % 15 M kr
E. Öhman J :or Fonder AB
2.230 %
1,328,635 2.230 % 14 M kr
LSP Advisory BV
1.420 %
845,886 1.420 % 9 M kr
Renée Aguiar-Lucander
1.079 %
643,000 1.079 % 7 M kr
NameEquities%Valuation
BVF, Inc.
2.518 %
750,000 2.518 % 16 M kr
DWS Investment GmbH
0.1697 %
50,550 0.1697 % 1 M kr
Ironwood Investment Management LLC
0.0854 %
25,435 0.0854 % 534 389 kr
Susquehanna Securities LLC
0.0316 %
9,412 0.0316 % 197 746 kr
Wells Fargo Clearing Services LLC
0.005035 %
1,500 0.005035 % 31 515 kr
Vision2020 Wealth Management Corp.
0.003934 %
1,172 0.003934 % 24 624 kr
Optiver Holding BV
0.003290 %
980 0.003290 % 20 590 kr
UBS Securities LLC
0.003196 %
952 0.003196 % 20 002 kr
Planning Capital Management Corp.
0.002944 %
877 0.002944 % 18 426 kr
Citadel Securities GP LLC
0.002776 %
827 0.002776 % 17 375 kr

Holdings

NameEquities%Valuation
CALLIDITAS THERAPEUTICS AB
9.92%
 5,908,018 9.92% 62,657,308 $

Company contact information

Calliditas Therapeutics AB

D5, Kungsbron 1

111 22, Stockholm

+46 84 11 30 05

http://www.pharmalink.se
address Calliditas Therapeutics AB(CALTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
103.7 SEK
Average target price
208 SEK
Spread / Average Target
+100.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
CALLIDITAS THERAPEUTICS AB Stock Calliditas Therapeutics AB
-17.47% 508M
MERCK KGAA Stock Merck KGaA
+3.57% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+19.75% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. Company Calliditas Therapeutics AB